Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MC4R | P32245 | 14/20 | 0.61 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.43 |
| ▸ | TACR1 | P25103 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | MC3R | P41968 | 2/20 | 0.41 |
| ▸ | MC1R | Q01726 | 2/20 | 0.41 |
| ▸ | MC5R | P33032 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13798834 | 0.92 | MC4R (0.62) | MC4RSMYD3TACR1MEN1KMT2A | |
| SCHEMBL13790198 | 0.91 | MC4R (0.70) | MC4RTACR1MC3RMC1RMC5R | |
| SCHEMBL13790254 | 0.91 | MC4R (0.70) | MC4RTACR1MC3RMC1RMC5R | |
| SCHEMBL4511343 | 0.91 | MC4R (0.70) | MC4RTACR1MC3RMC1RMC5R | |
| SCHEMBL4506555 | 0.89 | MC4R (0.61) | MC4RSMYD3TACR1MEN1KMT2A | |
| SCHEMBL13790200 | 0.88 | MC4R (0.67) | MC4RTACR1MC3RMC1RMC5R | |
| SCHEMBL4515822 | 0.87 | MC4R (0.61) | MC4RSMYD3TACR1MC3RMC1R | |
| SCHEMBL5479784 | 0.86 | MC4R (0.61) | MC4RSMYD3TACR1MEN1KMT2A | |
| SCHEMBL5478540 | 0.85 | MC4R (0.59) | MC4RSMYD3TACR1MC3RMC5R | |
| SCHEMBL4519546 | 0.83 | MC4R (0.54) | MC4RSMYD3TACR1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070265248-A1 | Substituted piperazines and methods of use | AMGEN INC. (US) | 2007-11-15 | — | — | US | claimed |
| US-20030220324-A1 | Substituted piperazines and methods of use | AMGEN INC. | 2003-11-27 | — | — | US | claimed |
| US-7560460-B2 | Substituted piperazines and methods of use | AMGEN INC. (US) | 2009-07-14 | — | — | US | disclosed |
| US-7560460-B2 | Substituted piperazines and methods of use | AMGEN INC. (US) | 2009-07-14 | — | — | US | disclosed |
| EP-1417190-B1 | SUBSTITUTED PIPERAZINES AS MODULATORS OF THE MELANOCORTIN RECEPTOR | AMGEN INC (US) | 2008-10-22 | — | — | EP | disclosed |
| US-20070265248-A1 | Substituted piperazines and methods of use | AMGEN INC. (US) | 2007-11-15 | — | — | US | disclosed |
| US-20070265248-A1 | Substituted piperazines and methods of use | AMGEN INC. (US) | 2007-11-15 | — | — | US | disclosed |
| US-20070265248-A1 | Substituted piperazines and methods of use | AMGEN INC. (US) | 2007-11-15 | — | — | US | disclosed |
| US-7115607-B2 | Substituted piperazinyl amides and methods of use | AMGEN INC. (US) | 2006-10-03 | — | — | US | disclosed |
| US-20030220324-A1 | Substituted piperazines and methods of use | AMGEN INC. | 2003-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030220324-A1 | Substituted piperazines and methods of use | MC5R, MC4R, MC1R | MC4R 2/4885SMYD3 3756/4885TACR1 126/4885 |
| US-20070265248-A1 | Substituted piperazines and methods of use | MC5R, MC4R, MC1R | MC4R 2/4885SMYD3 3756/4885TACR1 126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.